Suven will present the key biology data in animal models of cognition and brain microdialysis on SUVN-502, a potent, selective brain penetrant and orally active 5-HT6 receptor antagonist for the symptomatic treatment of Alzheimer's disease.
The company's scientists will also present a paper on new animal model for Alzheimer's disease with dual blockade of cholinergic and glutametertic neural system induced memory impairment in rats, according to a press release on Monday.
Alzheimer's disease has a significant unmet medical need for which current treatment options are insufficient.
Suven has a number of discovery programmes in te area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients, the release added.
You’ve hit your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app